719722--2/10/2009--CARDIODYNAMICS_INTERNATIONAL

related topics

{product, candidate, development}

{product, liability, claim}

{acquisition, growth, future}

{product, market, service}

{stock, price, share}

{condition, economic, financial}

{stock, price, operating}

{operation, international, foreign}

{property, intellectual, protect}

{personnel, key, retain}

{debt, indebtedness, cash}

{customer, product, revenue}

{tax, income, asset}

{control, financial, internal}

{regulation, government, change}

{regulation, change, law}

The recent global economic and financial market crisis has had and may continue to have a negative effect on our business and operations. We depend upon our BioZ product line, which is in its early stages of market acceptance. Our success depends in part upon the availability of adequate third-party reimbursement. A low stock price could result in our being de-listed from the Nasdaq Market and subject us to regulations that could reduce our ability to raise funds. Capital markets are currently experiencing a period of dislocation and instability, which has had and could continue to have a negative impact on the availability and cost of capital. To service or retire our debt when and as due, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. Our quarterly operating results frequently vary due to factors outside our control. Our future financial results could be adversely impacted by asset impairments or other charges. We may need additional capital, which may be unavailable. Technological change is difficult to predict and new product transitions are difficult to manage. We depend on management and other key personnel. We must maintain and develop strategic relationships with third parties to increase market penetration of our product lines. If market conditions cause us to reduce the selling price of our products or sensors, our margins and operating results will decrease. We are subject to stock exchange and government regulation. We may not have adequate intellectual property protection. We face competition from other companies and technologies. We may not receive approvals by foreign regulators that are necessary for international sales. Our international sales expose us to unique risks. We may not be able to manage growth successfully. Our limited order backlog makes it difficult to predict sales and plan manufacturing requirements, which can lead to lower revenues, higher expenses and reduced margins. We depend on third parties for development and manufacturing services. Our common stock is subject to price volatility. We have a history of losses and may experience continued losses. We may not continue to receive necessary FDA or other regulatory clearances or approvals. We may not be able to make future acquisitions or successfully integrate any such acquisitions. We are subject to product liability claims and product recalls that may not be covered by insurance. We do not know the effects of healthcare reform proposals. We do not intend to pay dividends in the foreseeable future.

Full 10-K form ▸

719722--2/10/2009--CARDIODYNAMICS_INTERNATIONAL_CORP